Erythropoiesis-stimulating agents in chronic kidney disease: What have we learned in 25 years?

Journal of the Formosan Medical Association

Volumn 113, Issue 1, 2014, Pages 3-10

  Hung, Szu Chun ^a   Lin, Yao Ping ^b,c   Tarng, Der Cherng ^b,c  

^a TZU CHI UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Anemia; Chronic kidney disease; Erythropoiesis stimulating agents; Erythropoietin; Hemodialysis

Indexed keywords

ANTIANEMIC AGENT;

ANEMIA; BLOOD TRANSFUSION; BLOOD VISCOSITY; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; DRUG MEGADOSE; ERYTHROPOIESIS; HEMATOCRIT; HUMAN; HYPERPLASIA; HYPERTENSION; INDIVIDUALIZATION; KIDNEY GRAFT; MORBIDITY; REVIEW; THROMBOCYTOSIS; TUMOR GROWTH; DRUG EFFECTS; KIDNEY FAILURE, CHRONIC;

ANEMIA; ERYTHROPOIESIS; HEMATINICS; HUMANS; KIDNEY FAILURE, CHRONIC;

EID: 84892554663     PISSN: None     EISSN: 09296646     Source Type: Journal    
DOI: 10.1016/j.jfma.2013.09.004     Document Type: Review

References (53)

1. Eschbach J.W., Egrie J.C., Downing M.R., Browne J.K., Adamson J.W. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987, 316:73-78.
2. Eschbach J.W., Kelly M.R., Haley N.R., Abels R.I., Adamson J.W. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 1989, 321:158-163.
3. Eschbach J.W., Abdulhadi M.H., Browne J.K., Delano B.G., Downing M.R., Egrie J.C., et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease: results of a phase III multicenter clinical trial. Ann Intern Med 1989, 111:992-1000.
4. Freburger J.K., Ng L.J., Bradbury B.D., Kshirsagar A.V., Brookhart M.A. Changing patterns of anemia management in US hemodialysis patients. Am J Med 2012, 125:906-914.
5. Chang Y.T., Pan S.Y., Lin S.L. Seeking for a way to revive erythropoietin production in chronic kidney disease. JFormos Med Assoc 2013, 112:657-658. 10.1016/j.jfma.2013.04.005.
6. Bernhardt W.M., Wiesener M.S., Scigalla P., Chou J., Schmieder R.E., Gunzler V., et al. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol 2010, 21:2151-2156.
7. Miyake T., Kung C.K.-H., Goldwasser E. Purification of human erythropoietin. J Biol Chem 1977, 252:5558-5564.
8. Lin F.K., Suggs S., Lin C.H., Browne J.K., Smalling R., Egrie J.C., et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci 1985, 82:7580-7584.
9. Peces R., de la Torre M., Alcázar R., Urra J.M. Antibodies against recombinant human erythropoietin in a patient with erythropoietin-resistant anemia. N Engl J Med 1996, 335:523-524.
10. Rossert J., Casadevall N., Eckardt K.U. Anti-erythropoietin antibodies and pure red cell aplasia. J Am Soc Nephrol 2004, 15:398-406.
11. Macdougall I.C., Rossert J., Casadevall N., Stead R.B., Duliege A.M., Froissart M., et al. A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. N Engl J Med 2009, 361:1848-1855.
12. Fishbane S., Schiller B., Locatelli F., Covic A.C., Provenzano R., Wiecek A., et al. Peginesatide in patients with anemia undergoing hemodialysis. N Engl J Med 2013, 368:307-319.
13. Macdougall I.C., Provenzano R., Sharma A., Spinowitz B.S., Schmidt R.J., Pergola P.E., et al. Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis. N Engl J Med 2013, 368:320-332.
14. Winearls C.G., Oliver D.O., Pippard M.J., Reid C., Downing M.R., Cotes P.M. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1986, 328:1175-1178.
15. Besarab A., Bolton W.K., Browne J.K., Egrie J.C., Nissenson A.R., Okamoto D.M., et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998, 339:584-590.
16. Singh A.K., Szczech L., Tang K.L., Barnhart H., Sapp S., Wolfson M., et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006, 355:2085-2098.
17. Drüeke T.B., Locatelli F., Clyne N., Eckardt K.U., Macdougall I.C., Tsakiris D., et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006, 355:2071-2084.
18. Pfeffer M.A., Burdmann E.A., Chen C.Y., Cooper M.E., de Zeeuw D., Eckardt K.U., et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009, 361:2019-2032.
19. Bohlius J., Schmidlin K., Brillant C., Schwarzer G., Trelle S., Seidenfeld J., et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009, 373:1532-1542.
20. Winkelmayer W.C. Against treating all patients alike: lessons from an FDA advisory committee meeting. J Am Soc Nephrol 2011, 21:1-2.
21. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int Suppl 2012, 2:279-335.
22. Choukroun G., Kamar N., Dussol B., Etienne I., Cassuto-Viguier E., Toupance O., et al. Correction of postkidney transplant anemia reduces progression of allograft nephropathy. J Am Soc Nephrol 2012, 23:360-368.
23. Yeh P.Y., Liao F.L., Lin S.L. Reply to Comment on: Is the renoprotective effect of erythropoietin in chronic kidney disease a myth?. J Formos Med Assoc 2013, 113:63-64. 10.1016/j.jfma.2013.03.005.
24. Park S.H., Choi M.J., Song I.K., Choi S.Y., Nam J.O., Kim C.D., et al. Erythropoietin decreases renal fibrosis in mice with ureteral obstruction: role of inhibiting TGF-β-induced epithelial-to-mesenchymal transition. J Am Soc Nephrol 2007, 18:1497-1507.
25. Heinze G., Kainz A., Horl W.H., Oberbauer R. Mortality in renal transplant recipients given erythropoietins to increase haemoglobin concentration: cohort study. BMJ 2009, 339:b4018.
26. Szczech L.A., Barnhart H.X., Inrig J.K., Reddan D.N., Sapp S., Califf R.M., et al. Secondary analysis of the CHOIR trial epoetin-α dose and achieved hemoglobin outcomes. Kidney Int 2008, 74:791-798.
27. Raine A.E. Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy. Lancet 1998, 331:97-100.
28. Goodkin D.A., Fuller D.S., Robinson B.M., Combe C., Fluck R., Mendelssohn D., et al. Naturally occurring higher hemoglobin concentration does not increase mortality among hemodialysis patients. J Am Soc Nephrol 2011, 22:358-365.
29. Hampl H., Hennig L., Rosenberger C., Amirkhalily M., Gogoll L., Riedel E., et al. Effects of optimized heart failure therapy and anemia correction with epoetin β on left ventricular mass in hemodialysis patients. Am J Nephrol 2005, 25:211-220.
30. Streja E., Kovesdy C.P., Greenland S., Kopple J.D., McAllister C.J., Nissenson A.R., et al. Erythropoietin, iron depletion, and relative thrombocytosis: A possible explanation for hemoglobin-survival paradox in hemodialysis. Am J Kidney Dis 2008, 52:727-736.
31. Kalantar-Zadeh K., Regidor D.L., McAllister C.J., Beckie M., Warnock D.G. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 2005, 16:3070-3080.
32. Hung S.C., Tarng D.C. Bone marrow iron in CKD: correlation with functional iron deficiency. Am J Kidney Dis 2010, 55:617-621.
33. Young B., Zaritsky A. Hepcidin for clinicians. Clin J Am Soc Nephrol 2009, 4:1384-1387.
34. Coyne D.W., Kapoian T., Suki W., Singh A.K., Moran J.E., Dahl N.V., et al. Ferric gluconate is highly efficacious in anemic patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron With Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 2007, 18:975-984.
35. Vogel J., Gassmann M. Erythropoietic and non-erythropoietic functions of erythropoietin (Epo) in mouse models. J Physiol 2011, 589:1259-1264.
36. Liu Y., Xu Y., Thilo F., Friis U.G., Jensen B.L., Scholze A., et al. Erythropoietin increases expression and function of transient receptor potential canonical 5 channels. Hypertension 2011, 58:317-324.
37. Brines M., Cerami A. Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise. Kidney Int 2006, 70:246-250.
38. Janmaat M.L., Heerkens J.L., de Bruin A.M., Klous A., de Waard V., de Vries C.J. Erythropoietin accelerates smooth muscle cell-rich vascular lesion formation in mice through endothelial cell activation involving enhanced PDGF-BB release. Blood 2010, 115:1453-1460.
39. Hedley B.D., Allan A.L., Xenocostas A. The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression. Clin Cancer Res 2011, 17:6373-6380.
40. Xue Y., Lim S., Yang Y., Wang Z., Jensen L.D., Hedlund E.M., et al. PDGF-BB modulates hematopoiesis and tumor angiogenesis by inducing erythropoietin production in stromal cells. Nat Med 2012, 18:100-110.
41. Rizzo J.D., Brouwers M., Hurley P., Seidenfeld J., Arcasoy M.O., Spivak J.L., et al. American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood 2010, 116:4045-4059.
42. Solomon S.D., Uno H., Lewis E.F., Eckardt K.U., Lin J., Burdmann E.A., et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med 2012, 363:1146-1155.
43. Ifudu O., Feldman J., Friedman E.A. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. N Engl J Med 1996, 334:420-425.
44. Tarng D.C., Huang T.P., Chen T.W., Yang W.C. Erythropoietin hyporesponsiveness: from iron deficiency to iron overload. Kidney Int 1999, 55:S107-S118.
45. Lin C.L., Huang C.C., Yu C.C., Wu C.H., Chang C.T., Hsu H.H., et al. Improved iron utilization and reduced erythropoietin resistance by on-line hemodiafiltration. Blood Purif 2002, 20:349-356.
46. Cooper A., Mikhail A., Lethbridge M.W., Kemeny D.M., Macdougall I.C. Pentoxifylline improves hemoglobin levels in patients with erythropoietin resistant anemia in renal failure. J Am Soc Nephrol 2004, 15:1877-1882.
47. Tarng D.C., Wei Y.H., Huang T.P., Kuo B.I., Yang W.C. Intravenous ascorbic acid as an adjuvant therapy for recombinant erythropoietin in hemodialysis patients with hyperferritinemia. Kidney Int 1999, 55:2477-2486.
48. Tarng D.C., Huang T.P. A parallel, comparative study of intravenous iron versus intravenous ascorbic acid for erythropoietin-hyporesponsive anaemia in haemodialysis patients with iron overload. Nephrol Dial Transplant 1998, 13:2867-2872.
49. Goldsmith D. A requiem for rHuEPOs-but should we nail down the coffin in 2010?. Clin J Am Soc Nephrol 2009, 2010(5):929-935.
50. Kliger A.S., Fishbane S., Finkelstein F.O. Erythropoietic stimulating agents and quality of a patient's life: Individualizing anemia treatment. Clin J Am Soc Nephrol 2012, 7:354-357.
51. Bright R. Cases and observations: illustrative of renal disease accompanied by the secretion of albuminous urine. Guys Hosp Rep 1836, 1:338.
52. Jacobson L.O., Goldwasser E., Fried W., Plzak L. Role of the kidney in erythropoiesis. Nature 1957, 179:633-634.
53. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 2006, 47:S11-145. KDOQI National Kidney Foundation.